| Literature DB >> 25847770 |
Arianna Nencini1, Carmela Pratelli2, Joanna M Quinn3, Massimiliano Salerno2, Patrizia Tunici2, Alessandra De Robertis2, Silvia Valensin2, Federica Mennillo2, Marco Rossi2, Annette Bakker4, Tiziana Benicchi5, Federico Cappelli2, Elisa Turlizzi2, Martina Nibbio6, Nicola P Caradonna2, Ugo Zanelli7, Matteo Andreini2, Matteo Magnani2, Maurizio Varrone8.
Abstract
Wnt signaling pathway plays a critical role in numerous cellular processes, including tumor initiation, proliferation, invasion/infiltration, metastasis formation and resistance to chemotherapy. In a drug discovery project aimed at the identification of inhibitors of the canonical Wnt pathway, we selected a series of quinazoline 2,4-diones as starting point for the therapeutic treatment of glioblastoma multiforme. Despite of poor physico-chemical properties of hit compound 1, our medicinal chemistry effort allowed the discovery and characterization of lead compound 33 (SEN461), with improved ADME profile, good bioavailability and active in vitro and in vivo in glioblastoma, gastric and sarcoma tumors.Entities:
Keywords: Glioblastoma; Small molecule; Structure–activity relationship; Wnt pathway; β-catenin
Mesh:
Substances:
Year: 2015 PMID: 25847770 DOI: 10.1016/j.ejmech.2015.03.055
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514